A double blind trial of carbenoxolone and geranyl farnesyl acetate in gastric ulcer.
57 patients with a chronic gastric ulcer were treated as outpatients in a double blind comparison of carbenozolone 100 mg three times daily with the same dose of geranyl farnesyl acetate (Gefarnate). Healing rates for carbenoxolone were better than for gefarnate, but not significantly so. Nearly half the carbenoxolone-treated patients developed hypokalaemia or oedema, whereas no similar side-effects were found with gefarnate. Gefarnate, while not as effective as carbenoxolone, does appear to promote gastric ulcer healing. Its virtual absence of side-effects makes it a safe and useful drug.
D002229:Carbenoxolone / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005231:Fatty Acids, Unsaturated / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D010919:Placebos; D013276:Stomach Ulcer / Q000188:drug therapy*; D013729:Terpenes / Q000627:therapeutic use*; D014315:Triterpenes / Q000627:therapeutic use*
D005231:Fatty Acids, Unsaturated; D010919:Placebos; D013729:Terpenes; D014315:Triterpenes; D002229:Carbenoxolone